Clinical Trial Update: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy and safety of Orelabrutinib in adults with chronic immune thrombocytopenia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Chronic Primary Immune Thrombocytopenia (ITP) | Phase 3 | Status: RECRUITING